Plasma neurofilament light chain levels in chemotherapy‐induced peripheral neurotoxicity according to type of anticancer drug.
Saved in:
| Title: | Plasma neurofilament light chain levels in chemotherapy‐induced peripheral neurotoxicity according to type of anticancer drug. |
|---|---|
| Authors: | Velasco, Roser (AUTHOR), Marco, Carla (AUTHOR), Domingo‐Domenech, Eva (AUTHOR), Stradella, Agostina (AUTHOR), Santos, Cristina (AUTHOR), Laquente, Berta (AUTHOR), Ferrer, German (AUTHOR), Argyriou, Andreas A. (AUTHOR), Bruna, Jordi (AUTHOR) |
| Source: | European Journal of Neurology. Sep2024, Vol. 31 Issue 9, p1-9. 9p. |
| Subjects: | Nerve conduction studies, End of treatment, Antineoplastic agents, Cytoplasmic filaments, Paclitaxel |
| Abstract: | Background and purpose: A real‐time biomarker in chemotherapy‐induced peripheral neurotoxicity (CIPN) would be useful for clinical decision‐making during treatment. Neurofilament light chain (NfL) can be detected in blood in the case of neuroaxonal damage. The aim of the study was to compare the levels of plasma NfL (pNfL) according to the type of chemotherapeutic agent and the severity of CIPN. Methods: This single‐center prospective observational longitudinal study included patients treated with paclitaxel (TX; n = 34), brentuximab vedotin (BV; n = 29), or oxaliplatin (PT; n = 19). All patients were assessed using the Total Neuropathy Score–clinical version and Common Terminology Criteria for Adverse Events before, during, and up to 6–12 months after the end of treatment. Nerve conduction studies (NCS) were performed before and after chemotherapy discontinuation. Consecutive plasma samples were analyzed for NfL levels using a Simoa® analyzer. Changes in pNfL were compared between groups and were eventually correlated with clinical and NCS data. Clinically relevant (CR) CIPN was considered to be grade ≥ 2. Results: Eighty‐two patients, mostly women (59.8%), were included. One third of the patients who received TX (29.4%), BV (31%), or PT (36.8%) developed CR‐CIPN, respectively, without differences among them (p = 0.854). Although pNfL significantly increased during treatment and decreased throughout the recovery period in all three groups, patients receiving TX showed significantly greater and earlier changes in pNfL levels compared to the other agents (p < 0.001). Conclusions: A variable change in pNfL is observed depending on the type of agent and mechanism of neurotoxicity with comparable CIPN severity, strongly implying the need to identify different cutoff values for each agent. [ABSTRACT FROM AUTHOR] |
| Copyright of European Journal of Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Background and purpose: A real‐time biomarker in chemotherapy‐induced peripheral neurotoxicity (CIPN) would be useful for clinical decision‐making during treatment. Neurofilament light chain (NfL) can be detected in blood in the case of neuroaxonal damage. The aim of the study was to compare the levels of plasma NfL (pNfL) according to the type of chemotherapeutic agent and the severity of CIPN. Methods: This single‐center prospective observational longitudinal study included patients treated with paclitaxel (TX; n = 34), brentuximab vedotin (BV; n = 29), or oxaliplatin (PT; n = 19). All patients were assessed using the Total Neuropathy Score–clinical version and Common Terminology Criteria for Adverse Events before, during, and up to 6–12 months after the end of treatment. Nerve conduction studies (NCS) were performed before and after chemotherapy discontinuation. Consecutive plasma samples were analyzed for NfL levels using a Simoa® analyzer. Changes in pNfL were compared between groups and were eventually correlated with clinical and NCS data. Clinically relevant (CR) CIPN was considered to be grade ≥ 2. Results: Eighty‐two patients, mostly women (59.8%), were included. One third of the patients who received TX (29.4%), BV (31%), or PT (36.8%) developed CR‐CIPN, respectively, without differences among them (p = 0.854). Although pNfL significantly increased during treatment and decreased throughout the recovery period in all three groups, patients receiving TX showed significantly greater and earlier changes in pNfL levels compared to the other agents (p < 0.001). Conclusions: A variable change in pNfL is observed depending on the type of agent and mechanism of neurotoxicity with comparable CIPN severity, strongly implying the need to identify different cutoff values for each agent. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 13515101 |
| DOI: | 10.1111/ene.16369 |
